New Sales Methods at Invitrogen Help Drive 30-Percent Q3 Revenue Growth | GenomeWeb

Invitrogen’s US sales force was recently given new marching orders on how to sell the company’s wide line of products, and this shift has quickly provided top-line benefits to the firm, Greg Lucier, CEO and chairman, told analysts last week during the company’s third-quarter conference call.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.